Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients

Background Rapid decreases in activated CD4+ and CD8+ (HLA-DR + and CD38+ co-expressed) T-lymphocytes have been described within 1–2 weeks of initiating direct-acting antiviral (DAA) therapy among chronic Hepatitis C (CHC) patients. However, it is not known whether these changes are maintained past...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology international 2019-05, Vol.13 (3), p.270-276
Main Authors: Emmanuel, Benjamin, El-Kamary, Samer S., Magder, Laurence S., Stafford, Kristen A., Charurat, Man E., Poonia, Bhawna, Chairez, Cheryl, McLaughlin, Mary, Hadigan, Colleen, Masur, Henry, Kottilil, Shyam
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Antiviral drugs
CD38 antigen
CD4 antigen
CD4-Positive T-Lymphocytes - immunology
CD8 antigen
Cell activation
Clinical Trials as Topic
Cohort Studies
Colorectal Surgery
Correlation analysis
Female
Flow Cytometry
Hepacivirus - immunology
Hepatitis
Hepatitis C
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Hepatology
Histocompatibility antigen HLA
HIV
HIV Infections
Human immunodeficiency virus
Humans
Immune clearance
Immunology
Interferon
Lymphocytes
Lymphocytes T
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Patients
Phenotypes
Recovery (Medical)
Retrospective Studies
Surgery
Sustained Virologic Response
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Rapid decreases in activated CD4+ and CD8+ (HLA-DR + and CD38+ co-expressed) T-lymphocytes have been described within 1–2 weeks of initiating direct-acting antiviral (DAA) therapy among chronic Hepatitis C (CHC) patients. However, it is not known whether these changes are maintained past sustained virologic response (SVR), particularly in those who are HIV/HCV-coinfected. Methods We investigated the changes in immune parameters of T-lymphocytes from pre-DAA therapy to post-SVR among HIV negative and HIV positive patients with CHC. Repeated measurements of activated CD4+ and CD8+ T cells were analyzed by flow cytometry at pre-DAA therapy, DAA therapy, end of treatment, SVR, and post-SVR. A general linear model for repeated measurements was used to estimate the mean outcome at each timepoint and change between timepoints. Results HCV-monoinfected ( n  = 161) and HIV/HCV-coinfected ( n  = 59) patients who achieved SVR with DAA therapy were predominately middle aged, male, black, and non-cirrhotic. At pre-DAA therapy, HCV-monoinfected patients had significantly higher CD4+ T cells and CD4+:CD8+ T-cell ratio, while significantly lower CD8+ and activated CD4+ and CD8+ T cells compared to HIV/HCV-coinfected patients ( p  
ISSN:1936-0533
1936-0541
DOI:10.1007/s12072-019-09941-8